早期使用右美托咪定与中重度创伤性脑损伤临床及功能结局的关联:一项TRACK-TBI研究
该回顾性队列研究纳入TRACK-TBI中18家一级创伤中心352例年龄>17岁、GCS<13且需机械通气的msTBI患者,采用倾向加权模型分析ICU入科5天内早期右美托咪定暴露与6个月GOS-E等结局的关联。早期右美托咪定暴露77例(22%),通常作为二线药物。全人群中早期右美托咪定与6个月GOS-E无显著关联(加权OR=1.48;95%CI 0.98-2.25),与更低DRS相关(加权OR=-3.04;95%CI -5.88至-0.21)。在入院24小时内需ICP监测的患者中,早期右美托咪定与更高6个月GOS-E(OR 2.17;95%CI 1.24-3.80)、更低DRS(校正均数差-5.81;95%CI -9.38至2.25)和更短住院时间(HR=1.50;95%CI 1.02-2.20)相关。
要点
- 全人群中早期右美托咪定暴露与6个月GOS-E无显著关联(加权OR=1.48;95%CI 0.98-2.25)。
- 全人群中早期右美托咪定暴露与更低6个月DRS相关(加权OR=-3.04;95%CI -5.88至-0.21)。
- 入院24小时内需ICP监测者中,早期右美托咪定与更高6个月GOS-E相关(OR 2.17;95%CI 1.24-3.80)。
- 需ICP监测者中,早期右美托咪定与更低DRS(校正均数差-5.81;95%CI -9.38至2.25)和更短住院时间相关(HR=1.50;95%CI 1.02-2.20)。
- 初始镇静药以丙泊酚为主(240例,68%),右美托咪定初始仅3例(1%),早期右美托咪定多作为二线药物(77例,22%)。
适用人群与场景
- 美国18家一级创伤中心、TRACK-TBI研究中年龄>17岁、GCS<13且入院24小时内需机械通气的中重度创伤性脑损伤成人患者,共352例。
诊断标准与关键阈值
- 中重度TBI定义为格拉斯哥昏迷评分(GCS)<13。
- 早期右美托咪定暴露定义为ICU入科后前5天内使用右美托咪定。
研究设计与关键结果
- 研究类型为回顾性队列研究,数据前瞻性收集,纳入18家一级创伤中心352例需机械通气的msTBI患者。
- 初始镇静药物:丙泊酚240例(68%)、咪达唑仑59例(17%)、氯胺酮6例(2%)、右美托咪定3例(1%),43例(12%)未接受持续镇静。
- 早期右美托咪定暴露77例(22%),通常作为二线药物。
- 主要终点:早期右美托咪定暴露与未暴露相比,6个月GOS-E无显著关联(加权OR=1.48;95%CI 0.98-2.25)。
- 次要终点:早期右美托咪定暴露与更低6个月DRS相关(加权OR=-3.04;95%CI -5.88至-0.21)。
- 入院24小时内需ICP监测的患者中,早期右美托咪定暴露与更高6个月GOS-E相关(OR 2.17;95%CI 1.24-3.80),与更低DRS相关(校正均数差-5.81;95%CI -9.38至2.25),与更短住院时间相关(HR=1.50;95%CI 1.02-2.20)。
证据类型、等级与局限
- 证据类型:回顾性队列研究(数据前瞻性收集),采用倾向加权模型。
- 局限:原文未报告局限性。
对床旁实践的改变
- 中重度TBI机械通气患者早期镇静选择存在差异,早期右美托咪定暴露在全人群中未显示与6个月功能结局改善相关,但在有ICP监测指征的患者中可能带来临床获益(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine early sedation patterns, as well as the association of dexmedetomidine exposure, with clinical and functional outcomes among mechanically ventilated patients with moderate-severe traumatic brain injury (msTBI).
DESIGN: Retrospective cohort study with prospectively collected data.
SETTING: Eighteen Level-1 Trauma Centers, United States.
PATIENTS: Adult (age > 17) patients with msTBI (as defined by Glasgow Coma Scale < 13) who required mechanical ventilation from the Transforming Clinical Research and Knowledge in TBI (TRACK-TBI) study.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Using propensity-weighted models, we examined the association of early dexmedetomidine exposure (within the first 5 d of ICU admission) with the primary outcome of 6-month Glasgow Outcomes Scale Extended (GOS-E) and the following secondary outcomes: length of hospital stay, hospital mortality, 6-month Disability Rating Scale (DRS), and 6-month mortality. The study population included 352 subjects who required mechanical ventilation within 24 hours of admission. The initial sedative medication was propofol for 240 patients (68%), midazolam for 59 patients (17%), ketamine for 6 patients (2%), dexmedetomidine for 3 patients (1%), and 43 patients (12%) never received continuous sedation. Early dexmedetomidine was administered in 77 of the patients (22%), usually as a second-line agent. Compared with unexposed patients, early dexmedetomidine exposure was not associated with better 6-month GOS-E (weighted odds ratio [OR] = 1.48; 95% CI, 0.98-2.25). Early dexmedetomidine exposure was associated with lower DRS (weighted OR = -3.04; 95% CI, -5.88 to -0.21). In patients requiring ICP monitoring within the first 24 hours of admission, early dexmedetomidine exposure was associated with higher 6-month GOS-E score (OR 2.17; 95% CI, 1.24-3.80), lower DRS score (adjusted mean difference, -5.81; 95% CI, -9.38 to 2.25), and reduced length of hospital stay (hazard ratio = 1.50; 95% CI, 1.02-2.20).
CONCLUSION: Variation exists in early sedation choice among mechanically ventilated patients with msTBI. Early dexmedetomidine exposure was not associated with improved 6-month functional outcomes in the entire population, although may have clinical benefit in patients with indications for ICP monitoring.
参考来源
- Liu SY, Kelly-Hedrick M, Temkin N, et al. Association of Early Dexmedetomidine Utilization With Clinical and Functional Outcomes Following Moderate-Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study. Crit Care Med. 2023. PMID: 37966330. doi:10.1097/CCM.0000000000006106
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。